Counterpoint Mutual Funds LLC Buys 1,458 Shares of Encompass Health Co. (NYSE:EHC)

Counterpoint Mutual Funds LLC lifted its stake in shares of Encompass Health Co. (NYSE:EHC) by 53.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,187 shares of the company’s stock after purchasing an additional 1,458 shares during the quarter. Counterpoint Mutual Funds LLC’s holdings in Encompass Health were worth $387,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. KBC Group NV boosted its position in Encompass Health by 11.3% during the 3rd quarter. KBC Group NV now owns 2,757 shares of the company’s stock worth $266,000 after buying an additional 279 shares during the period. OneDigital Investment Advisors LLC acquired a new stake in Encompass Health during the 3rd quarter worth approximately $207,000. CIBC Asset Management Inc boosted its position in Encompass Health by 3.5% during the 3rd quarter. CIBC Asset Management Inc now owns 2,957 shares of the company’s stock worth $286,000 after buying an additional 100 shares during the period. Natixis Advisors LLC boosted its position in Encompass Health by 7.8% during the 3rd quarter. Natixis Advisors LLC now owns 101,296 shares of the company’s stock worth $9,789,000 after buying an additional 7,294 shares during the period. Finally, Thrivent Financial for Lutherans boosted its position in Encompass Health by 26.0% during the 3rd quarter. Thrivent Financial for Lutherans now owns 760,496 shares of the company’s stock worth $73,494,000 after buying an additional 156,938 shares during the period. 97.25% of the stock is owned by institutional investors.

Insider Buying and Selling at Encompass Health

In other news, CAO Andrew L. Price sold 5,042 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $98.29, for a total value of $495,578.18. Following the completion of the sale, the chief accounting officer now owns 69,164 shares in the company, valued at $6,798,129.56. This represents a 6.79 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 2.10% of the stock is currently owned by company insiders.

Encompass Health Stock Performance

NYSE:EHC opened at $97.73 on Tuesday. The company has a fifty day moving average of $97.48 and a 200-day moving average of $97.01. The firm has a market capitalization of $9.84 billion, a P/E ratio of 21.91, a P/E/G ratio of 2.31 and a beta of 0.92. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84. Encompass Health Co. has a twelve month low of $74.45 and a twelve month high of $104.55.

Encompass Health (NYSE:EHC) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.17 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.12. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. As a group, sell-side analysts anticipate that Encompass Health Co. will post 4.8 EPS for the current year.

Encompass Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Tuesday, April 1st will be paid a dividend of $0.17 per share. The ex-dividend date is Tuesday, April 1st. This represents a $0.68 dividend on an annualized basis and a yield of 0.70%. Encompass Health’s dividend payout ratio (DPR) is presently 15.25%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. William Blair reiterated an “outperform” rating on shares of Encompass Health in a research report on Friday, February 7th. StockNews.com upgraded shares of Encompass Health from a “hold” rating to a “buy” rating in a research report on Saturday, February 15th. Royal Bank of Canada restated an “outperform” rating and issued a $110.00 price target on shares of Encompass Health in a research report on Tuesday, February 11th. KeyCorp boosted their price target on shares of Encompass Health from $117.00 to $120.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Finally, Barclays boosted their price target on shares of Encompass Health from $116.00 to $118.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. Ten equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Encompass Health presently has an average rating of “Buy” and a consensus target price of $107.67.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.